Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Metrics to compare | BAVA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBAVAPeersSector | |
---|---|---|---|---|
P/E Ratio | 11.8x | −5.1x | −0.6x | |
PEG Ratio | 0.24 | −0.23 | 0.00 | |
Price/Book | 1.2x | 2.7x | 2.6x | |
Price / LTM Sales | 2.2x | 20.3x | 3.1x | |
Upside (Analyst Target) | 63.8% | 85.2% | 51.8% | |
Fair Value Upside | Unlock | 11.5% | 8.3% | Unlock |